-
公开(公告)号:US20130053382A1
公开(公告)日:2013-02-28
申请号:US13643580
申请日:2011-04-28
申请人: Sunil Paliwal , Matthew Paul Rainka , Ang Li , May Xiaowu Jiang , Hon-chung Tsui , Ronald J. Doll
发明人: Sunil Paliwal , Matthew Paul Rainka , Ang Li , May Xiaowu Jiang , Hon-chung Tsui , Ronald J. Doll
IPC分类号: C07D417/14 , A61K31/5377 , A61P35/00 , A61K31/4725 , A61K31/454 , A61K31/4439 , A61K31/427 , A61K31/496
CPC分类号: C07D417/04 , C07D417/14
摘要: The instant invention provides for compounds that inhibit PDK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting PDK1 activity by administering the compound to a patient in need of treatment of cancer.
摘要翻译: 本发明提供抑制PDK1活性的化合物。 本发明还提供了包含这种抑制化合物的组合物和通过将该化合物给予需要治疗癌症的患者来抑制PDK1活性的方法。
-
2.N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 失效
标题翻译: 3-磷酸腺苷依赖性蛋白激酶-1的N-苯基咪唑酰胺酰胺抑制剂公开(公告)号:US20130079326A1
公开(公告)日:2013-03-28
申请号:US13699547
申请日:2011-05-24
申请人: Hon-Chung Tsui , Sunil Paliwal , Hyunjin M. Kim , Angela D. Kerekes , Mary Ann Caplen , Sara J. Esposite , Brian A. McKittrick , Thierry Olivier Fischmann , Ronald J. Doll , Matthew Paul Rainka
发明人: Hon-Chung Tsui , Sunil Paliwal , Hyunjin M. Kim , Angela D. Kerekes , Mary Ann Caplen , Sara J. Esposite , Brian A. McKittrick , Thierry Olivier Fischmann , Ronald J. Doll , Matthew Paul Rainka
IPC分类号: A61K45/06 , A61K31/454 , C07D401/14 , A61K31/4545 , C07D405/14 , A61K31/4178 , A61K31/4995 , A61K31/437 , C07D413/14 , A61K31/5377 , A61K31/551 , C07D403/04 , C07D409/14 , A61K31/506
CPC分类号: A61K45/06 , A61K31/4178 , A61K31/437 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K31/551 , A61K31/69 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/08 , C07D491/10 , C07D498/08 , A61K2300/00
摘要: The present invention provide Imidazole Carboxamide Compounds of Formula (I): wherein D, T, R1, R2, R3, and R6 are as defined herein, and pharmaceutically acceptable salts of such Imidazole Carboxamide Compounds. The Imidazole Carboxamide Compounds are useful in the treatment of cancer and other aberrant conditions that result from overstimulation of the PDK-1 signaling pathway.
摘要翻译: 本发明提供式(I)的咪唑羧酰胺化合物:其中D,T,R 1,R 2,R 3和R 6如本文所定义,以及这些咪唑羧酰胺化合物的药学上可接受的盐。 咪唑羧酰胺化合物可用于治疗由过度刺激PDK-1信号通路引起的癌症和其他异常病症。
-
3.N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 失效
标题翻译: 3-磷酸肌醇依赖性蛋白激酶-1的N-苯基咪唑甲酰胺抑制剂公开(公告)号:US08623857B2
公开(公告)日:2014-01-07
申请号:US13699547
申请日:2011-05-24
申请人: Hon-Chung Tsui , Sunil Paliwal , Hyunjin M. Kim , Angela D. Kerekes , Mary Ann Caplen , Sara J. Esposite , Brian A. McKittrick , Thierry Olivier Fischmann , Ronald J. Doll , Matthew Paul Rainka , Ang Li
发明人: Hon-Chung Tsui , Sunil Paliwal , Hyunjin M. Kim , Angela D. Kerekes , Mary Ann Caplen , Sara J. Esposite , Brian A. McKittrick , Thierry Olivier Fischmann , Ronald J. Doll , Matthew Paul Rainka , Ang Li
IPC分类号: C07D498/08 , C07D243/00 , C07D401/14 , C07D409/14 , C07D405/14 , C07D413/14 , C07D403/04 , A61K31/5386 , A61K31/5377 , A61K31/506 , A61K31/551 , A61K31/454 , A61K31/4545 , A61K31/4178 , A61K31/437 , A61K31/4995 , A61K45/06
CPC分类号: A61K45/06 , A61K31/4178 , A61K31/437 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K31/551 , A61K31/69 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/08 , C07D491/10 , C07D498/08 , A61K2300/00
摘要: The present invention provide Imidazole Carboxamide Compounds of Formula (I): wherein D, T, R1, R2, R3, and R6 are as defined herein, and pharmaceutically acceptable salts of such Imidazole Carboxamide Compounds. The Imidazole Carboxamide Compounds are useful in the treatment of cancer and other aberrant conditions that result from overstimulation of the PDK-1 signaling pathway.
摘要翻译: 本发明提供式(I)的咪唑羧酰胺化合物:其中D,T,R 1,R 2,R 3和R 6如本文所定义,以及这些咪唑羧酰胺化合物的药学上可接受的盐。 咪唑羧酰胺化合物可用于治疗由过度刺激PDK-1信号通路引起的癌症和其他异常病症。
-
-